Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases [Yahoo! ...
Eterna Therapeutics Inc. (ERNA)
Company Research
Source: Yahoo! Finance
CAMBRIDGE, Mass. Oct. 17, 2024 "We are excited to collaborate with Factor to unlock the full potential of these transformative cell therapies," said Sanjeev Luther , Eterna's President & CEO. "Our focus at Eterna has always been on developing transformative treatments for patients with difficult-to-treat diseases, and we believe this collaboration agreement increases our potential to rapidly advance therapies that target solid tumors, rare diseases, and autoimmune disorders." Factor and Eterna will collaborate on data generation that seeks to demonstrate efficacy of the licensed drug candidates for development towards IND by Eterna directly or with third-party sublicensees. As part of the agreement, Factor is entitled to receive milestone payments per product candidate, as well as post-commercialization royalties. "We are thrilled to support Eterna's pipeline of advanced cell therapy product candidates," said Matt Angel , Ph.D., CEO of Factor. "Eterna's team has deep translatio
Show less
Read more
Impact Snapshot
Event Time:
ERNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERNA alerts
High impacting Eterna Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ERNA
News
- Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models [Yahoo! Finance]Yahoo! Finance
- Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer ModelsGlobeNewswire
- Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program [Yahoo! Finance]Yahoo! Finance
- Eterna Therapeutics Announces Up to $1 Million Stock Repurchase ProgramGlobeNewswire
- Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing [Yahoo! Finance]Yahoo! Finance
ERNA
Sec Filings
- 11/18/24 - Form 424B3
- 11/18/24 - Form 424B3
- 11/18/24 - Form 424B3
- ERNA's page on the SEC website